Neonatalnutrition: Scott C. Denne
Neonatalnutrition: Scott C. Denne
Neonatalnutrition: Scott C. Denne
Scott C. Denne, MD
KEYWORDS
Infant nutrition Breastfeeding Infant formula Gastroesophageal reflux
KEY POINTS
There is good evidence of the clinical benefit of breastfeeding to infants and mothers, and
it should be the primary nutrition source for most infants.
The breastfed infant is the normative model for infant growth, and the WHO growth curves
should be used for all term infants.
All standard term infant formulas are clinically equivalent and adequately support growth
for the small proportion of infants who cannot breastfeed.
Soy and other specialized formulas should be reserved for particular circumstances and
conditions and should not be used routinely.
Gastroesophageal reflux occurs in most infants and does not require intervention. Gastro-
esophageal reflux disease occurs in a small proportion of infants and an algorithm-based
evaluation and management strategy should be used.
NEONATAL NUTRITION
There is accumulating evidence that nutrition and growth in early life can have
substantial influences on adult health.1 This article reviews the current knowledge,
recommendations, and approaches to feeding the normal newborn. The current un-
derstanding and approach to the common and sometimes difficult problem of gastro-
esophageal reflux (GER) in normal infants is also discussed.
BREASTFEEDING
Based on the many demonstrated benefits for babies and mothers, the World Health
Organization (WHO), the American Academy of Pediatrics (AAP), and Institute of
Medicine recommend the exclusive use of human milk for healthy term infants for
the first 6 months of life, and continued breastfeeding for at least 12 months.2
The public health goal for Healthy People 2020 is for 82% of mothers to initiate breast-
feeding, 60% of mothers to be breastfeeding at 6 months, and 34% to be breastfeed-
ing at 1 year.3 The Centers for Disease Control and Prevention (CDC) tracks these
breastfeeding rates and issues a breastfeeding report card yearly.4 Significant prog-
ress has been made toward achieving these breastfeeding goals, and in 2011 79%
of women initiated breastfeeding. However, additional progress is necessary in the
duration and exclusivity of breastfeeding. The most recent data on breastfeeding rates
and the goals of Healthy People 2020 are shown in Fig. 1.
To support higher breastfeeding rates, additional objectives of Healthy People 2020
include increasing the proportion of employers that have worksite lactation support
programs, reducing the number of breastfed newborns who receive formula supple-
mentation within the first 2 days of life, and increasing the proportion of live births
that occur in facilities that provide recommended care for lactating mothers and their
babies.3
Although there has been progress in overall breastfeeding rates, these gains have
not been uniform across all populations and geographic regions.5 Breastfeeding rates
are lower for black infants, infants of mothers with lower incomes, and mothers with
less education.5–7 Breastfeeding rates are lower in the southern United States and
in rural areas.5,8 Health care workers should be aware of these disparities so that
they can focus their attention on these groups to educate about and support breast-
feeding, and help others overcome barriers to breastfeeding.
Fig. 1. US breastfeeding rates in 2011 (red bars) and Healthy People 2020 goals (green bars).
BF, breastfed. (Data from National Center for Chronic Disease Prevention and Health Promo-
tion. Breast feeding report card. Atlanta, GA: CDC, 2014. Available at: www.cdc.gov/pdf/
2014breastfeedingreportcard.pdf. Accessed November 3, 2014.)
Neonatal Nutrition 429
Box 1
Reduction in disease/condition associated with breastfeeding
Infant
Otitis media
Recurrent otitis media
Respiratory tract infection
Asthma
Atopic dermatitis
Gastroenteritis
Type 1 and 2 diabetes
Leukemia
Sudden infant death syndrome
Mother
Breast cancer
Ovarian cancer
Data from Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare Research
and Quality’s evidence report on breastfeeding in developed countries. Breastfeed Med
2009;4 Suppl 1:S17–30.
430 Denne
composition remains stable for the next several months.11 The change in macronu-
trient concentration in human milk over time is shown in Fig. 2.
The macronutrient mineral, vitamin, and micronutrient concentration of mature hu-
man milk is shown in Table 1. It must be pointed out that Table 1 lists average compo-
sition values; there is substantial variability in the nutrient content of human milk
across individual mothers. Furthermore, aliquots of milk from one mother can also
be quite different in composition. However, the mother-infant dyad seems to success-
fully adapt to these variations, and successful breastfeeding and normal infant growth
is achieved for most mothers and infants.
Human milk contains live cells and a large variety of bioactive substances.5,10 Mac-
rophages, T cells, and lymphocytes are all found in human milk, with macrophages be-
ing the predominant cell type. These cells most likely perform an important host
defense function for the infant. Multiple bioactive factors are present in human milk
including immunoglobulins, growth factors, cytokines, and other small molecules. A
partial list of bioactive substances contained in human milk along with their proposed
function is shown in Table 2.
Fig. 2. Change in macronutrient composition of human milk over time. (Data from Gidre-
wicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of pre-
term and term breast milk. BMC Pediatr 2014;14(1):216.)
Neonatal Nutrition 431
Table 1
Concentrations of selected nutrients in mature (2 wk) human milk
Energy 66 9 kcal
Protein 1.3 0.2 g
Fat 3.0 0.9 g
Lactose 6.2 0.6 g
Calcium 28 7 mg
Phosphorus 15 4 mg
Sodium 18 4 mg
Potassium 53 4 mg
Chloride 42 6 mg
Iron 0.03 0.01 mg
Vitamin D 2.2 0.4 IU/100 mL
WHO growth curves for all children younger than 24 months. These growth charts are
readily available on the CDC Web site (www.cdc.gove/growthcharts/who_charts.htm).
Table 2
Selected bioactive compounds in human milk
Data from Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL): American
Academy of Pediatrics; 2014; and Ballard O, Morrow AL. Human milk composition: nutrients and
bioactive factors. Pediatr Clin North Am 2013;60(1):49–74.
432 Denne
Duration of Breastfeeding
The AAP, WHO, and Institute of Medicine recommend exclusive breastfeeding for
about 6 months, with continuation after complementary foods have been introduced
for at least the first year of life.2,5 Breastfeeding can be extended beyond the first
year of life as mutually desired by the mother and child. It is important to point out
that the definition of exclusive breastfeeding includes the administration of vitamin
D and iron.
Contraindications to Breastfeeding
There are a limited number of medical circumstances where breastfeeding is contra-
indicated. These include some maternal infections, particular inborn errors of meta-
bolism in infants, and a few maternal medications.
Maternal medical conditions that preclude breastfeeding include human T-cell lym-
photropic virus (type 1 and 2), untreated brucellosis, active pulmonary tuberculosis
without 2 weeks of completed treatment, and active herpes simplex lesions on
the breast.2,5 In the industrialized world, breastfeeding is also contraindicated for
HIV-positive mothers. Because the primary carbohydrate of breast milk is lactose, a
disaccharide composed of glucose and galactose, infants with the inborn error of
metabolism of galactosemia should not be breastfed. Although most maternal medi-
cations are compatible with breastfeeding, certain medications are a contraindication
to breastfeeding, such as mothers receiving antineoplastic drug therapy. Because of
the rapidly changing information on medications relative to breastfeeding, it is advis-
able to consult the drugs and lactation database (LacMed) before making a determi-
nation. LacMed is easily accessible from the US National Library of Medicine Web site
(http://docsnet.nlm.nih.gov).
Supporting Breastfeeding
Providing support to the breastfeeding mother requires appropriate institutional pol-
icies and the knowledge and attention of health care providers. To ensure that breast-
feeding is supported in the hospital, the World Health Organization has provided 10
steps to successful breastfeeding (Box 2). The 10-step program has been effective
in increasing rates of breastfeeding initiation, exclusivity, and duration.13
Following hospital discharge, the primary care physician should see all breastfeed-
ing newborns at 3 to 5 days of age or within 48 to 72 hours after discharge from the
hospital.2 At this visit, the physician should evaluate body weight and establish that
weight loss is no more than 7% from birth, and that there is no further weight loss
by Day 5. If weight loss is of concern, feeding should be assessed and more frequent
follow-up should be scheduled. Infant elimination patterns should be discussed and
hydration evaluated. One feeding should be observed and any other maternal and in-
fant issues discussed.
Box 2
World Health Organization ten steps to successful breastfeeding
1. Have a written breastfeeding policy that is routinely communicated to all health care staff.
2. Train all health care staff in the skills necessary to implement this policy.
3. Inform all pregnant women about the benefits and management of breastfeeding.
4. Help mothers initiate breastfeeding within the first hour of birth.
5. Show mothers how to breastfeed and how to maintain lactation even if they are separated
from their infants.
6. Give newborn infants no food or drink other than breast milk, unless medically indicated.
7. Practice rooming-in (allow mothers and infants to remain together) 24 hours a day.
8. Encourage breastfeeding on demand.
9. Give no artificial nipples or pacifiers to breastfeeding infants.a
10. Foster the establishment of breastfeeding support groups and refer mothers to them on
discharge from hospital.
a
The AAP does not support a categorical ban on pacifiers because of their role in sudden in-
fant death syndrome risk reduction and their analgesic benefit during painful procedures.
From World Health Organization. Evidence for the Ten Steps to Successful Breastfeeding.
Geneva, Switzerland, 1998. Available at: www.who.int/nutrition/publications/evidence_ten_
step_eng.pdf. Accessed November 3, 2014.
can occur in 10% to 20% of mothers. Treatment consists of frequent and effective milk
removal and sometimes antibiotics.
Although breastfeeding is preferred for most normal healthy term infants, formula
feeding can support nutrition and growth. The indications for the use of infant formulas
include (1) as a substitute (or as a supplement) for human milk in infants whose
mothers choose not to breastfeed or not to do so exclusively, (2) as a substitute for
human milk in infants where breastfeeding is medically contraindicated, and (3) as a
supplement for breastfed infants who’s intake of human milk does not support
adequate weight gain.5 It must be noted that the supplementation should be instituted
only after interventions to increase milk supply have been ineffective.
Infant Formulas
Infant formulas are regulated by the Food and Drug Administration and manufacturers
must ensure by analysis the amount of 29 essential nutrients in each batch of for-
mula.15 All commercially available standard term infant formulas in the United States
support normal growth and development of healthy term infants. Although products
from different manufacturers may vary slightly in their nutrient composition, the prod-
ucts are much more similar than different. At present, there is no clinical evidence that
differences in term infant formulas have any important measurable clinical effects, and
there is no medical reason to prefer one brand over another.
Infant formulas are available in ready to feed, in concentrated liquid, and in powder.
Proper preparation of the liquid concentrate and the powder forms is essential, and
detailed instructions are found on each manufacturer’s Web site. Standard infant for-
mula contains 19 or 20 calories per ounce, which is similar to the average caloric con-
tent of breast milk (recognizing the previously discussed variability of human milk).
434 Denne
However, infant formula contains about a 50% higher amount of protein than human
milk (approximately 1.4 g/100 mL protein in infant formula). The amount of fat in infant
formula is similar to human milk (approximately 3.6 g/100 mL); the fat is provided pri-
marily by mixtures of vegetable oils. Most infant formula manufacturers have added
very long chain polyunsaturated fatty acids (arachidonic acid and docosahexaenoic
acid) to their formulas. These compounds may help to promote brain and visual devel-
opment, although the long-term benefit of these additives seems to be minimal or
nonexistent.16 There are, however, no safety concerns by the addition of docosahex-
aenoic acid and arachidonic acid to infant formulas. The carbohydrate concentration
in infant formula (approximately 7.5 g/100 mL) and composition (predominantly
lactose) is similar to human milk.
All standard infant formulas contain iron, ideally at a concentration of 12 mg/L. This
concentration of iron prevents development of iron deficiency and anemia. However,
low-iron infant formulas continue to be available based on a perception of gastrointes-
tinal (GI) symptoms (colic, constipation) with the use of higher-iron formulas. However,
multiple well-controlled studies have consistently failed to demonstrate any difference
in GI symptoms between higher and lower iron-containing formulas. It is the position of
the AAP that there is no role for low-iron formulas in the feeding of healthy term infants.5
Soy Formulas
Although the routine use of soy formulas is not recommended, current commercially
available soy formulas adequately support growth and bone mineralization of healthy
term infants.17,18 All soy formulas are lactose free, and can be used to feed infants who
cannot tolerate milk protein or lactose. The specific conditions where soy formula is
recommended and not recommended by the AAP is shown in Box 3.5,19
GER occurs in most infants (70%–85% within the first 2 months of life), and is often
seen as a problem by parents and physicians. However, it is clear that GER is part
Neonatal Nutrition 435
Box 3
AAP recommendations for the use of soy formula in term infants
Data from Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL): Amer-
ican Academy of Pediatrics; 2014; and Bhatia J, Greer F. Use of soy protein-based formulas in
infant feeding. Pediatrics 2008;121(5):1062–8.
of normal physiology and occurs multiple times a day in healthy infants, children, and
adults. Most infants have uncomplicated GER (“happy spitters”) and require no more
than parental education and reassurance. However, it is important to identify the small
portion of infants who have gastroesophageal reflux disease (GERD) who require addi-
tional evaluation, monitoring, and sometimes treatment. These issues are briefly dis-
cussed here; a variety of excellent and comprehensive recent reviews of GER and
GERD are available.19–24
dry rice cereal to 1 ounce of formula or by using a commercially thickened full term
infant formula.23 Thickened feedings are likely to have little effect on the actual num-
ber of reflux episodes but rather reduce the number of observed regurgitations.
There is no information on the long-term effects of thickened infant feedings. There
is a possible association between thickened feedings and necrotizing entercolitis in
preterm infants, and therefore commercial thickened infant formula should not be
used in infants born before 37 weeks gestation who have been discharged from
the hospital in the past 30 days.
Yes
Concerning symptoms present? Evaluate
(Bilious vomiƟng, GI bleeding, etc) further
No
Yes
Adequate caloric intake? EducaƟon, Close follow up
No
Yes
Abnormal? Manage accordingly
No
Dietary management:
Maternal exclusion diet if breasƞed; Protein hydrolysate if formula fed
Thickened feedings; Increased caloric density
Yes
Improved? EducaƟon, Close follow up
No
Fig. 3. Algorithm for the evaluation and management of infants with vomiting/regurgita-
tion and poor weight gain as developed by the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition and endorsed by the AAP. CBC, complete
blood count; GI, gastrointestinal; NG, nasogastric; NJ, nasojejunal; U/A, urinalysis. (Adapted
from Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clin-
ical practice guidelines: joint recommendations of the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol
Nutr 2009;49(4):498–547, with permission; and Lightdale JR, Gremse DA. Gastroesophageal
reflux: management guidance for the pediatrician. Pediatrics 2013;131(5):
e1684–95.)
Neonatal Nutrition 437
Although most infants with GER need only routine evaluation and minimal if
any intervention, infants with poor weight gain along with regurgitation and/or vomiting
require additional evaluation and possible treatment. An approach to the infant with
recurrent regurgitation and poor weight gain, as proposed by the North American So-
ciety for Gastroenterology, Hepatology and Nutrition, is shown in Fig. 3.20 After
ensuring that there are no significant concerning other symptoms and caloric intake
is adequate, evaluation consists of some screening blood work along with possibly
an upper GI tract series. An upper GI series is useful for evaluating a possible malro-
tation or duodenal web. If there is persistent or forced vomiting in the first few months
of life, pyloric ultrasonography should be performed to evaluate for pyloric stenosis. If
these screening tests are normal, a trial of dietary management can be initiated. For
breastfeeding mothers, a 2- to 4-week trial of a diet that restricts milk and egg is rec-
ommended; this is to address a potential milk protein allergy. For formula-fed infants,
some extensively hydrolyzed protein formula may be appropriate. In addition, thick-
ened feedings may also be useful.
If these interventions result in clinical improvement, they should be continued with
additional close follow-up. If there is no improvement, consultation with a pediatric
gastroenterologist should be strongly considered. Some consideration may be given
to acid-suppression therapy. Although treatment with a prokinetic (eg, metoclopra-
mide) may be considered, the risks of this therapy may outweigh the benefits.26
Indeed, metoclopramide carries a Food and Drug Administration black box warning
regarding its adverse effects. In general, use of pharmacologic therapy for infants
with GERD should be uncommon and likely requires comanagement with a pediatric
gastroenterologist.
REFERENCES
1. Robinson S, Fall C. Infant nutrition and later health: a review of current evidence.
Nutrients 2012;4(8):859–74.
2. Breastfeeding and the use of human milk. Pediatrics 2012;129(3):e827–41.
3. Healthy People 2020. Gov. Available at: http://www.healthypeople.gov/2020/
topics. Accessed November 3, 2014.
4. Centers for Disease Control and Prevention. Breastfeeding Report Card, United
States, 2014. Available at: www.cdc.gov/pdf/2014breastfeedingreportcard.pdf.
Accessed November 3, 2014.
5. Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL):
American Academy of Pediatrics; 2014.
6. Fein SB, Labiner-Wolfe J, Shealy KR, et al. Infant feeding practices study II: study
methods. Pediatrics 2008;122(Suppl 2):S28–35.
7. Ryan AS, Wenjun Z, Acosta A. Breastfeeding continues to increase into the new
millennium. Pediatrics 2002;110(6):1103–9.
8. U.S. Department of Health and Human Services. The Surgeon General’s Call to
Action to Support Breastfeeding. Washington (DC): U.S. Department of Health
and Human Services, Office of the Surgeon General; 2011.
9. Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare
Research and Quality’s evidence report on breastfeeding in developed countries.
Breastfeed Med 2009;4(Suppl 1):S17–30.
10. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors.
Pediatr Clin North Am 2013;60(1):49–74.
11. Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient
content of preterm and term breast milk. BMC Pediatr 2014;14(1):216.
438 Denne
12. de Onis M, Garza C, Onyango AW, et al. Comparison of the WHO child growth
standards and the CDC 2000 growth charts. J Nutr 2007;137(1):144–8.
13. World Health Organization. Evidence for the Ten Steps to Successful Breastfeed-
ing. Geneva, Switzerland, 1998. Available at: www.who.int/nutrition/publications/
evidence_ten_step_eng.pdf. Accessed November 3, 2014.
14. Bergmann RL, Bergmann KE, von Weizsacker K, et al. Breastfeeding is natural
but not always easy: intervention for common medical problems of breastfeeding
mothers. A review of the scientific evidence. J Perinat Med 2014;42(1):9–18.
15. Drugs Fa. 21 CFR 107. 2009. Available at: http://www.gpo.gov/fdsys/pkg/CFR-
2009-title21-vol1/content-detail.html. Accessed November 3, 2014.
16. Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid supplemen-
tation in infants born at term. Cochrane Database Syst Rev 2011;(12):CD000376.
17. Lasekan JB, Ostrom KM, Jacobs JR, et al. Growth of newborn, term infants fed
soy formulas for 1 year. Clin Pediatr 1999;38(10):563–71.
18. Venkataraman PS, Luhar H, Neylan MJ. Bone mineral metabolism in full-term in-
fants fed human milk, cow milk-based, and soy-based formulas. Am J Dis Child
1992;146(11):1302–5.
19. Bhatia J, Greer F. Use of soy protein-based formulas in infant feeding. Pediatrics
2008;121(5):1062–8.
20. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal re-
flux clinical practice guidelines: joint recommendations of the North American So-
ciety for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and
the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
(ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49(4):498–547.
21. Forbes D. Mewling and puking: infantile gastroesophageal reflux in the 21st cen-
tury. J Paediatr Child Health 2013;49(4):259–63.
22. Czinn SJ, Blanchard S. Gastroesophageal reflux disease in neonates and infants:
when and how to treat. Paediatr Drugs 2013;15(1):19–27.
23. Lightdale JR, Gremse DA. Gastroesophageal reflux: management guidance for
the pediatrician. Pediatrics 2013;131(5):e1684–95.
24. Rosen R. Gastroesophageal reflux in infants: more than just a phenomenon.
JAMA Pediatr 2014;168(1):83–9.
25. Kleinman L, Revicki DA, Flood E. Validation issues in questionnaires for diagnosis
and monitoring of gastroesophageal reflux disease in children. Curr Gastroen-
terol Rep 2006;8(3):230–6.
26. Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feed-
ings, and positioning for gastro-oesophageal reflux in children under two years.
Cochrane Database Syst Rev 2004;(4):CD003502.